Lupin Ties Up with Galenicum to Commercialise Injectable Semaglutide Across 23 Global Markets
Indian pharmaceutical major Lupin Limited has entered into a licensing and supply agreement with Spain-based Galenicum Health, S.L.U. to expand the global availability of injectable Semaglutide, a key GLP-1 receptor agonist used in the treatment of Type 2 diabetes and obesity.












